Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.47 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15453240 | 0.92 | TRIM24 (0.44) | TRIM24TRIM33CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL872115 | 0.81 | — | — | |
| SCHEMBL7072643 | 0.76 | — | — | |
| SCHEMBL444647 | 0.74 | — | — | |
| SCHEMBL15453315 | 0.74 | — | — | |
| SCHEMBL4450606 | 0.74 | — | — | |
| Bromide SCHEMBL27799185 | 0.74 | CYP3A4 (0.43) | CYP3A4CYP2D6CYP2C19TAAR1ALDH1A1 | |
| SCHEMBL2567146 | 0.74 | — | — | |
| SCHEMBL17868738 | 0.73 | CYP2C19 (0.40) | TRIM24TRIM33CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8284720 | 0.73 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19TAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-103408534-B | The synthesis technique of eletriptan | ZHANG JIA GANG VINSCE BIO-PHARM Co.,Ltd. (CN) | 2016-05-04 | — | — | CN | disclosed |
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| EP-2682399-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | Meiji Seika Pharma Co., Ltd. (JP) | 2014-01-08 | — | — | EP | disclosed |
| CN-103408534-A | Novel synthetic process of Eletriptan | ZHANGJIAGANG WEISHENG BIOLOG PHARMACEUTICAL CO LTD | 2013-11-27 | — | — | CN | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039171-A1 | NOVEL MACROLIDE INTERMEDIATE AND NOVEL PRODUCTION PROCESS | MRPL21, PIGS, CYP51A1 | TRIM24 1887/4885TRIM33 3910/4885CYP3A4 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.